ACG Engineering, which is a part of the ACG Group, has announced its acquisition of a German-based pharma processing equipment provider, Xertecs.
In an Aug. 1, 2019 press statement, ACG Engineering, which is a part of the ACG Group, has announced its acquisition of a German-based pharma processing equipment provider, Xertecs.
The acquisition follows from the long partnership that has been in place between the two companies and will add European design to the capabilities of ACG Engineering. The Xertecs facility and team, which are based in Mulheim, Germany, will become a Center of Excellence for ACG Engineering, serving as the ACG Innovation Centre Europe.
“This is a tremendous boost for our commitment to create next-generation machines that serve our pharmaceutical and nutraceutical customers,” said Richard Stedman, group CEO, ACG Engineering, in the press release. “The Xertecs team brings best-in-class design and product management skills to ACG Engineering. We are looking forward to developing a wide range of innovative, ground-breaking equipment solutions and best-practice initiatives between the two teams.”
Klaus Groeschel, managing director, sales & marketing for Xertecs added, “This represents a great opportunity for ACG to meet global design standards throughout its product portfolio. This is the next logical step in the relationship between our two businesses. The team at Xertecs is very enthusiastic for the opportunity to continue contributing to ACG’s global product offerings and service capabilities.”
Source:
ACG
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.